Format

Send to

Choose Destination
Leuk Res. 2018 Jul;70:56-61. doi: 10.1016/j.leukres.2018.05.008. Epub 2018 May 24.

Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma.

Author information

1
Department of Hematology, Peking Union Medical College Hospital, Beijing, China; Department of Minimally Invasive Intervention, Sun Yat-Sen University Cancer Center, Guangzhou, China.
2
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
3
Department of Hematology, Peking Union Medical College Hospital, Beijing, China. Electronic address: ZhangWei3840@pumch.cn.

Abstract

PURPOSE:

The aim of study was to explore the PD-1 expression on Treg cells and its association with T-NHL.

METHODS:

137 patients newly diagnosed with T-NHL and 115 healthy controls were enrolled. The expression level of PD-1 was measured by flow cytometry at the time of diagnose and 3-8 course of treatment.

RESULTS:

Median fluorescence intensity (MFI) of PD-1 on Treg cells in T-NHL patients was significantly higher than that in healthy controls (P < 0.001). MFI of PD-1 in medium/high-risk T-NHL patients were higher than that in low-risk patients (P < 0.05). After treatment with Chidamide combined with chemotherapy, MFI of PD-1 significantly decreased (P < 0.05). In patients with high PD-1 expression (percentage>19.6% and MFI > 580), EFS was significantly lower than patients with low PD-1 expression (percentage<19.6% and MFI < 580).

CONCLUSIONS:

The PD-1expression on peripheral blood Treg cells of T-NHL patients is related to the diagnosis, prognosis and treatment of disease.

KEYWORDS:

Peripheral blood; Programmed death-1; T cell non-Hodgkin lymphoma; Treg cell

PMID:
29859415
DOI:
10.1016/j.leukres.2018.05.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center